Company intelligence / Profile preview
Peptimmune
Cambridge, Massachusetts, United States
- Ownership
- Private
- Employees
- ~5
- Development stage
- Other
01
Overview
Peptimmune completed Phase Ib studies of PI-2301 in secondary progressive multiple sclerosis and conducted a Phase I trial of PI-0824 in pemphigus vulgaris. The company also licensed an anti-obesity product from Genzyme that reached early clinical development. Despite some positive results, the company filed for Chapter 7 bankruptcy in 2011 after failing to secure further funding.
- Therapeutic areas
- NeurologyDermatologyMetabolic Disorders
- Modalities
- Peptide copolymersbiologics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Genzyme Corp. (licensed anti-obesity product)
Beyond the preview
Go deeper on Peptimmune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peptimmune.